Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

11276	Companies
250579	Keywords
179215	Articles
136418	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 07/30/2025 at 15:00, 1 year 3 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center

Xenetic Biosciences DNase I PeriNess Large B Cell Lymphoma Anti-CD19 CAR T Cells
BRIEF

published on 07/23/2025 at 14:35, 1 year 3 months ago

Xenetic Biosciences étend sa collaboration avec Scripps Research

Biosciences Xénétiques Thérapie Par Cellules CAR-T Développement Préclinique Plateforme DNase-I Collaboration En Oncologie
BRIEF

published on 07/23/2025 at 14:35, 1 year 3 months ago

Xenetic Biosciences Expands Collaboration with Scripps Research

Xenetic Biosciences CAR T-cell Therapy Preclinical Development DNase-I Platform Oncology Collaboration
PRESS RELEASE

published on 07/23/2025 at 14:30, 1 year 3 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 1 year 3 months ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 1 year 3 months ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 1 year 3 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 1 year 5 months ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 1 year 5 months ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 1 year 5 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I

Accesswire

Published on 11/04/2026 at 23:10, 2 hours 27 minutes ago

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 2 hours 37 minutes ago

Avino Reports Q3 2026 Financial Results
Published on 11/04/2026 at 23:00, 2 hours 37 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 3 hours 22 minutes ago

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 3 hours 32 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 00:02, 1 hour 35 minutes ago

EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 5 hours 56 minutes ago

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 12 minutes ago

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 6 hours 54 minutes ago

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 7 hours 32 minutes ago

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production

Les Echos

Published on 11/04/2026 at 18:00, 7 hours 37 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 7 hours 37 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 7 hours 52 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 7 hours 52 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 7 hours 53 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE